CENTESSA PHARMACEUTICALS PLC Accumulated Other Comprehensive Income
CENTESSA PHARMACEUTICALS PLC had Accumulated Other Comprehensive Income of $1.41 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-05-05
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.41M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.71M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.60M.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.59M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-03-31 | $1.41M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $2.71M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.59M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $2.08M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.21M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.10M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.59M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.62M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $1.49M 10-K · filed 2025-03-24 |
| 2023-09-30 | $779.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $946.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$599.00K 10-Q · filed 2023-05-12 |
| 2022-12-31 | -$1.50M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$1.70M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$1.14M 10-Q · filed 2022-08-10 |
| 2022-03-31 | -$18.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $688.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.74M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $3.23M 10-Q · filed 2021-08-16 |